Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Colorectal Neoplasms 8Breast Neoplasms 7Polycythemia Vera 5Venous Thromboembolism 3Melanoma 3Colonic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Tobacco Use Disorder 2Thrombocythemia, Essential 2Smoking Cessation 2Rectal Neoplasms 2Prostatic Neoplasms 2Neoplastic Cells, Circulating 2Neoplasms 2Neoplasm Metastasis 2Myeloproliferative Disorders 2Multiple Myeloma 2Lung Neoplasms 2Barrett Esophagus 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Tuberous Sclerosis 1Thromboembolism 1Testicular Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Seizures 1Salivary Gland Neoplasms 1Recurrence 1Primary Myelofibrosis 1Precancerous Conditions 1

Interventions

Cyclophosphamide 59Dexamethasone 56Melphalan 48Peripheral Blood Stem Cell Transplantation 37Busulfan 34Bortezomib 32fludarabine phosphate 29Lenalidomide 27Filgrastim 27Tacrolimus 24Antilymphocyte Serum 24Thalidomide 22Mycophenolic Acid 22Radiotherapy 21Methotrexate 15Cyclosporine 15Etoposide 14sargramostim 13Granulocyte Colony-Stimulating Factor 11Whole-Body Irradiation 10Methylprednisolone 10Interferon-alpha 10fludarabine 9daratumumab 9Carmustine 9carfilzomib 7Rituximab 7Prednisone 7Cytarabine 7Cord Blood Stem Cell Transplantation 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms, Plasma Cell × Aspirin × Clear all
NCT00482261 2024-11-08

A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression

Peter MacCallum Cancer Centre, Australia

Phase 2 Completed
150 enrolled
Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡